Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kronos Bio Q3 2024 GAAP EPS $(0.23) Beats $(0.26) Estimate, Sales $2.37M Beat $2.10M Estimate

Author: Benzinga Newsdesk | November 13, 2024 04:26pm
Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. The company reported quarterly sales of $2.37 million which beat the analyst consensus estimate of $2.10 million by 12.86 percent. This is a 158.45 percent increase over sales of $917.00 thousand the same period last year.

Posted In: KRON


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist